Daily Cosmetic Research Analysis
A multicenter retrospective study suggests oral isotretinoin may be effective for acquired dermal macular hyperpigmentation with identifiable predictors of response. A comprehensive review proposes a practical, evidence-graded framework to extend "skinspan" via prevention-first strategies. A case report underscores late-onset granulomas causing trismus after soft-tissue fillers, emphasizing multidisciplinary management and regulation gaps.
Summary
A multicenter retrospective study suggests oral isotretinoin may be effective for acquired dermal macular hyperpigmentation with identifiable predictors of response. A comprehensive review proposes a practical, evidence-graded framework to extend "skinspan" via prevention-first strategies. A case report underscores late-onset granulomas causing trismus after soft-tissue fillers, emphasizing multidisciplinary management and regulation gaps.
Research Themes
- Therapeutic strategies for pigmentary disorders
- Prevention-focused frameworks for skin aging and longevity
- Safety and late complications of cosmetic injectables
Selected Articles
1. Treatment of Acquired Dermal Macular Hyperpigmentation With Oral Isotretinoin: A Multi-Institutional Retrospective Study of 121 Cases.
In a multicenter retrospective cohort (n=121), oral isotretinoin (commonly 20 mg/day for ~8 months) improved ADMH, with all Riehl’s melanosis and 90.4% of lichen planus pigmentosus patients showing improvement. Marked response was more frequent in RM (63.0%) than LPP (33.0%), and better outcomes associated with localized disease, shorter duration (<5 years), Fitzpatrick III–VI, and longer treatment.
Impact: This is the largest multi-institutional dataset evaluating isotretinoin for ADMH, identifying response predictors and providing actionable dosing/duration insights.
Clinical Implications: Consider off-label isotretinoin for refractory ADMH, especially in Riehl’s melanosis and localized, shorter-duration disease; anticipate better outcomes with longer courses and Fitzpatrick III–VI. Monitor for isotretinoin adverse effects and counsel patients on realistic timelines.
Key Findings
- Improvement in all RM and 90.4% of LPP cases; marked improvement in 63.0% (RM) and 33.0% (LPP).
- Better response with localized lesions (p=0.0012), disease duration <5 years (RM p=0.046; LPP p=0.0272), Fitzpatrick III–VI (p=0.0081), and longer treatment (p=0.0178).
- Most patients received 20 mg/day for an average of 8 months; RM responded better than LPP (p=0.005).
Methodological Strengths
- Multicenter, international cohort (121 patients) with standardized IGA assessment.
- Predefined subgroup analyses with statistical significance reporting.
Limitations
- Retrospective design without a control group limits causal inference.
- Heterogeneity in dosing and incomplete safety detail in the abstract.
Future Directions: Prospective controlled trials comparing isotretinoin with standard therapies, dose–response optimization, safety profiling, and biomarker-driven patient selection.
The term acquired dermal macular hyperpigmentation (ADMH) was introduced to unify Riehl's melanosis (RM), lichen planus pigmentosus (LPP), and related entities. These are cosmetically distressing pigmentary disorders that pose therapeutic challenges. To investigate the efficacy and safety of oral isotretinoin in treating ADMH, we conducted a muticenter retrospective study of patients with ADMH treated with oral isotretinoin between 2014 and 2024. Patients from Australia, China, Europe, India, Middle East, North America, and North Africa were included. Patients lost to follow-up before two visits were excluded. The response was graded by a 5-point Investigator's Global Assessment (IGA) scale. A total of 121 patients were included. Most patients (64.5%) were treated with a dose of 20 mg/d for an average of 8 months. Oral isotretinoin improved the severity of pigmentation in all RM and 85 (90.4%) LPP patients, with 17 (63.0%) RM and 31 (33.0%) LPP patients achieving marked improvement. RM patients responded better than LPP patients (p = 0.005). Patients with localized lesions (p = 0.0012), disease duration of less than 5 years (p = 0.046 for RM, p = 0.0272 for LPP), Fitzpatrick skin phototypes III-VI (p = 0.0081), or longer duration of treatment (p = 0.0178) responded better. Oral isotretinoin appears to be a promising treatment modality for ADMH.
2. Skinspan: A Holistic Roadmap for Extending Skin Longevity With Evidence-Based Interventions.
This comprehensive review introduces the "skinspan" framework and synthesizes molecular hallmarks of skin aging with graded evidence for interventions. It recommends first-line preventive measures (sun protection, topical retinoids, antioxidants), second-line device-based procedures, and considers emerging therapies as adjuncts pending stronger evidence.
Impact: It reframes aesthetic dermatology toward prevention and long-term skin health with an evidence-prioritized algorithm that can standardize consultations and care plans.
Clinical Implications: Adopt a prevention-first regimen for skin aging: daily photoprotection plus topical retinoids and antioxidants, escalating to energy-based devices as needed; reserve stem cell/sirtuin/nicotinamide-based approaches as adjuncts until supported by RCTs.
Key Findings
- Defines "skinspan" and aligns interventions with molecular hallmarks of aging (genomic instability, mitochondrial dysfunction, cellular senescence, proteostasis decline).
- First-line: photoprotection, topical retinoids, antioxidants; second-line: lasers/energy-based devices; third-line adjuncts: stem cell-based therapies, sirtuins, nicotinamide, natural SIRT activators.
- Calls for more randomized controlled trials to strengthen the evidence base for emerging therapies.
Methodological Strengths
- Integrates molecular geroscience with clinical interventions into a practical algorithm.
- Evidence grading across lifestyle, topical, systemic, and device-based modalities.
Limitations
- Narrative comprehensive review rather than a PRISMA-compliant systematic review.
- Heterogeneous evidence quality; limited RCT data for emerging modalities.
Future Directions: Randomized controlled trials testing preventive regimens, standardized outcome measures for "skinspan," and head-to-head comparisons of device-based and pharmacologic strategies.
BACKGROUND: With the rise of regenerative medicine and geroscience, translational research has shifted focus from lifespan to healthspan-years lived in good health. Applied to aesthetic medicine, the authors introduce the concept of "skinspan," to both describe the period during which skin maintains a youthful, healthy appearance, and additionally to serve as a tool for the cosmetic consult. AIMS: The aim of this comprehensive review is to illuminate "skinspan" as a framework for guiding long-term skin health. The authors review the molecular drivers of skin aging along with appraise current evidence-based interventions and synthesize evidence into an algorithm to expand skin span. METHODS: A comprehensive literature review was conducted to examine the molecular hallmarks of skin aging: genomic instability, mitochondrial dysfunction, cellular senescence, and proteostasis decline, and how they are targeted by lifestyle modifications, pharmacologic agents, and aesthetic procedures. Each intervention discussed in this paper is categorized based on the strength of the available evidence for augmenting skinspan. RESULTS: Proactive interventions, including lifestyle interventions, topical agents, systemic therapies, and noninvasive procedures, show promise in mitigating aging mechanisms and preserving skin health. We recommend a first-line strategy of sun protection, topical retinoids, and antioxidants. Second-line interventions include laser and energy-based devices. Clinicians may also consider emerging therapies-including stem cell-based treatments, sirtuins, nicotinamide, and natural SIRT activators-as adjunctive third-line add-ons, while continuing to monitor the evolving evidence base. CONCLUSION: The skinspan framework offers a holistic, evidence-based approach to skin longevity, promoting prevention, continuity of care, and patient education beyond isolated aesthetic interventions. To expand skinspan based on current evidence, we recommend a first-line approach of sun protection, topical retinoids, and antioxidants. Second-line interventions include procedures such as laser and energy-based devices. Clinicians may also consider emerging therapies-including stem cell-based treatments, sirtuins, nicotinamide, and natural SIRT activators-as adjunctive third-line add-ons, while continuing to monitor the evolving evidence base. A need exists for more randomized controlled trial studies to strengthen the evidence base.
3. Late complication of cosmetic injectable treatments presenting to oral and maxillofacial surgeons: soft tissue filler granulomas.
A case of trismus caused by intramasseteric granulomas after soft-tissue filler injections highlights a serious late-onset complication. The report emphasizes increasing complication rates, the role of oral and maxillofacial surgeons, and the need for collaboration with aesthetic clinicians in a largely unregulated treatment landscape.
Impact: Raises awareness of an uncommon but potentially debilitating filler complication, informing referral pathways and multidisciplinary management.
Clinical Implications: Clinicians should consider intramasseteric granuloma in patients presenting with trismus after fillers, expedite referral to oral and maxillofacial surgery, and establish collaborative management protocols.
Key Findings
- Reports trismus due to intramasseteric granulomas following soft-tissue filler injections.
- Highlights rising rates of complications after cosmetic treatments and the delayed-onset nature of granulomas.
- Stresses the need for collaboration between surgeons and aesthetic medicine clinicians amid limited regulation.
Methodological Strengths
- Clear clinical description of a rare, function-limiting complication.
- Contextualization within broader trends of increasing cosmetic treatment complications.
Limitations
- Single case report limits generalizability and cannot establish causality.
- Management details and long-term outcomes are not provided in the abstract.
Future Directions: Develop registries for filler complications, define imaging and treatment algorithms, and advance regulation and training standards for injectables.
Hospital-based clinicians have seen a progressive increase in complications following cosmetic treatments. A challenging late complication of soft tissue filler treatments is granuloma formation. Oral and maxillofacial surgeons have a key role in the discussion around this delayed-onset complication. We present a case of trismus arising from intramasseteric granulomas following soft-tissue filler injections. Collaboration between surgeons and aesthetic medicine clinicians is crucial to preventing and managing complications from treatments which remain largely unregulated.